New Hope for Kids and Adults with Spinal Muscular Atrophy

For more than 65 years, MDA has been on the frontlines of research for spinal muscular atrophy (SMA) and other neuromuscular diseases. We funded foundational work in SMA and invested in the early-stage development of nusinersen (brand name Spinraza). Today we celebrate FDA approval of this promising drug.

This advancement could not have been made possible without the amazing support of the MDA community over the years. Thank you to all who walked, ran, fundraised, dropped a dollar in a fireman’s boot, texted in a telethon donation or raised awareness online. You have made this life-changing achievement possible!